OncoMatch/Clinical Trials/NCT03391778
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
Is NCT03391778 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies ADP adoptive cell therapy for neoplasms.
Treatment: ADP adoptive cell therapy — This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Prior therapy
Must have received: adoptive cell therapy (ADP adoptive cell therapy agent, GSK adoptive cell therapy)
Participants who have received at least one dose of ADP adoptive cell therapy agent; Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Emory University School of Medicine · Atlanta, Georgia
- ADP Investigational Site · Baltimore, Maryland
- National Cancer Institute - Center for Cancer Research · Bethesda, Maryland
- University of Michigan · Ann Arbor, Michigan
- Washington University School of Medicine in St. Louis · St Louis, Missouri
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03391778 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received adoptive cell therapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify